NCT02840461

Clinical Endpoint Study of Ivermectin 1% Cream

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (Ivermectin) Cream 1% (Galderma) in the Treatment of Moderate to Severe Papulopustular Rosacea

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 630 (actual)
• Sponsor: Actavis Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin) cream 1% (Galderma) in the treatment of moderate to severe papulopustular rosacea.

Conditions

• Moderate to Severe Papulopustular Rosacea

Interventions

Type	Name	Description
DRUG	Ivermectin Cream, 1%
DRUG	Placebo/Vehicle cream

Timeline

• Start date: 2016-06-01
• Primary completion: 2016-11-01
• Completion: 2016-12-01
• First posted: 2016-07-21
• Last updated: 2020-06-02
• Results posted: 2020-06-02

Locations

1 site across 1 country: United States